Susquehanna International Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.07M Buy
48,200
+1,600
+3% +$38.2K ﹤0.01% 7707
2025
Q4
$1.24M Sell
46,600
-313,600
-87% -$7.49M ﹤0.01% 6670
2025
Q3
$7.69M Buy
360,200
+307,400
+582% +$7.27M ﹤0.01% 3400
2025
Q2
$1.14M Sell
52,800
-24,900
-32% -$463K ﹤0.01% 7109
2025
Q1
$1.29M Sell
77,700
-62,700
-45% -$1.14M ﹤0.01% 6612
2024
Q4
$2.58M Buy
140,400
+52,300
+59% +$844K ﹤0.01% 4754
2024
Q3
$1.35M Buy
88,100
+37,400
+74% +$624K ﹤0.01% 6143
2024
Q2
$824K Sell
50,700
-122,800
-71% -$1.98M ﹤0.01% 7053
2024
Q1
$3.21M Buy
173,500
+85,400
+97% +$2.12M ﹤0.01% 4389
2023
Q4
$2.76M Sell
88,100
-532,300
-86% -$12.7M ﹤0.01% 4724
2023
Q3
$12.9M Buy
620,400
+564,100
+1,002% +$15.3M ﹤0.01% 2237
2023
Q2
$1.35M Buy
56,300
+13,900
+33% +$309K ﹤0.01% 5999
2023
Q1
$798K Buy
42,400
+19,900
+88% +$379K ﹤0.01% 7419
2022
Q4
$358K Sell
22,500
-90,100
-80% -$1.41M ﹤0.01% 8670
2022
Q3
$1.84M Sell
112,600
-176,800
-61% -$2.86M ﹤0.01% 5083
2022
Q2
$4.08M Buy
289,400
+37,200
+15% +$694K ﹤0.01% 3520
2022
Q1
$6.11M Buy
252,200
+76,300
+43% +$1.85M ﹤0.01% 3310
2021
Q4
$4.11M Buy
175,900
+7,300
+4% +$147K ﹤0.01% 4089
2021
Q3
$2.8M Sell
168,600
-130,300
-44% -$2.51M ﹤0.01% 5096
2021
Q2
$7.29M Sell
298,900
-456,300
-60% -$10.3M ﹤0.01% 3374
2021
Q1
$19.5M Buy
755,200
+592,800
+365% +$26.1M ﹤0.01% 1905
2020
Q4
$8.68M Sell
162,400
-63,900
-28% -$3.17M ﹤0.01% 2666
2020
Q3
$9.34M Buy
226,300
+50,600
+29% +$2.19M ﹤0.01% 2264
2020
Q2
$8.52M Buy
175,700
+77,600
+79% +$3.73M ﹤0.01% 2337
2020
Q1
$4.14M Sell
98,100
-454,200
-82% -$18.7M ﹤0.01% 2820
2019
Q4
$23.6M Sell
552,300
-6,700
-1% -$291K 0.01% 1272
2019
Q3
$20.1M Buy
559,000
+13,200
+2% +$400K 0.01% 1323
2019
Q2
$14.6M Buy
545,800
+23,300
+4% +$595K 0.01% 1536
2019
Q1
$14M Sell
522,500
-203,000
-28% -$4.74M 0.01% 1465
2018
Q4
$11.7M Sell
725,500
-179,600
-20% -$3.49M ﹤0.01% 1463
2018
Q3
$18.8M Buy
905,100
+359,200
+66% +$5.65M 0.01% 1372
2018
Q2
$8.34M Sell
545,900
-359,500
-40% -$6.41M ﹤0.01% 2124
2018
Q1
$20.3M Buy
905,400
+407,900
+82% +$11.3M 0.01% 1198
2017
Q4
$15M Sell
497,500
-18,400
-4% -$588K 0.01% 1477
2017
Q3
$19.4M Sell
515,900
-88,400
-15% -$2.88M 0.01% 1249
2017
Q2
$16.9M Sell
604,300
-338,900
-36% -$10.1M 0.01% 1280
2017
Q1
$32.4M Sell
943,200
-324,900
-26% -$11.5M 0.02% 776
2016
Q4
$36.6M Buy
1,268,100
+400,600
+46% +$10.6M 0.02% 696
2016
Q3
$27.6M Hold
867,500
0.01% 811
2016
Q2
$28.2M Sell
867,500
-471,200
-35% -$15.8M 0.02% 778
2016
Q1
$37.4M Buy
1,338,700
+373,200
+39% +$8.14M 0.02% 650
2015
Q4
$34.4M Buy
965,500
+106,500
+12% +$3.75M 0.02% 793
2015
Q3
$28.4M Buy
859,000
+291,400
+51% +$12.1M 0.01% 946
2015
Q2
$23.8M Sell
567,600
-180,800
-24% -$7M 0.01% 1158
2015
Q1
$24.4M Buy
748,400
+197,200
+36% +$6.78M 0.01% 1090
2014
Q4
$17.5M Buy
551,200
+60,800
+12% +$1.72M 0.01% 1459
2014
Q3
$12.1M Sell
490,400
-48,300
-9% -$1.13M ﹤0.01% 1901
2014
Q2
$12.2M Sell
538,700
-19,100
-3% -$399K 0.01% 1903
2014
Q1
$13.6M Buy
557,800
+289,500
+108% +$7.32M 0.01% 1663
2013
Q4
$6.71M Sell
268,300
-34,200
-11% -$807K ﹤0.01% 2533
2013
Q3
$8.31M Sell
302,500
-107,600
-26% -$2.25M ﹤0.01% 2097
2013
Q2
$7.44M Buy
+410,100
New +$5.65M ﹤0.01% 2147

Other funds holding ACAD

Susquehanna International Group's ACAD Position: Q1 2026 in Review

Susquehanna International Group increased its Acadia Pharmaceuticals (ACAD) stake by 117% in Q1 2026, buying an estimated $577K and bringing the position to 44,792 shares worth $997K. The position accounts for ﹤0.01% of the portfolio, ranked #7897.

Susquehanna International Group first reported a position in ACAD in Q2 2013 and has held it in 50 quarters since. The position peaked at $32.3M in Q4 2014. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Susquehanna International Group held 44,792 shares of Acadia Pharmaceuticals worth $997K as of Q1 2026.
  • Susquehanna International Group bought 24,140 Acadia Pharmaceuticals shares in Q1 2026, an estimated $577K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7897 holding.
  • Susquehanna International Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Susquehanna International Group's Acadia Pharmaceuticals position peaked at $32.3M in Q4 2014.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.